April 1, 2019 – April 1, 2019 – Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.
Category: Uncategorized
FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic
February 25, 2019 – Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.
FACIT in the News – @globeandmail
February 6, 2019 – “For innovation, open science means open for business”, February 6, 2019
FACIT in the News – @globeandmail
January 29, 2019 – “U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
January 29, 2019 – Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.
FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack
January 10, 2019 – FACIT’s Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT’s early-stage Prospects Oncology Fund, illustrating FACIT’s strategy to ensure promising companies grow roots and scale up in Ontario.
Read More from FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack
FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray
November 12, 2018 – KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.
FACIT Welcomes Har Grover and Ken Lawless to the Board
October 11, 2018 – Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.
Read More from FACIT Welcomes Har Grover and Ken Lawless to the Board
FACIT Invests in Three Top Ontario Entrepreneur-Teams from Near Record Pool of Applicants
September 13, 2018 – With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.
Healthcare Software Start-Up Ziliomics Financed by FACIT
June 27, 2018 – Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.
Read More from Healthcare Software Start-Up Ziliomics Financed by FACIT